To evaluate the T1rho (T 1 ) MRI relaxation time in hippocampus in the brain of Alzheimer's disease (AD), mild cognitive impairment (MCI), and control, and to determine whether the T 1 shows any significant difference between these cohorts.
ALZHEIMER'S DISEASE (AD) is the most common form of neurodegenerative disorder in elderly and results in progressive memory loss and cognitive decline. The appearance of senile plaques and neurofibrillary tangles are the neuropathological hallmarks of AD (1) . Autopsy studies have shown the hippocampus to be affected by AD pathology early in the disease process, with Ϸ20%-50% loss of neurons by the time individuals are moderately affected (2, 3) . As a result, imaging studies have focused on this region in order to detect the early changes during the disease progression.
Currently the diagnosis of clinically probable AD can be confirmed only once the stage of dementia has been reached. Neuropsychological tests are necessary to recognize and monitor the subjects at risk. However, to date there is no accurate cognitive marker to identify AD in the early disease process. Moreover, cognitive performances depend not only on age and education but also on mood and attention at the time of testing, and thus lack wide generalizability. Quantitative analysis of tau protein and amyloid-A␤ in the cerebrospinal fluid (CSF) has shown some diagnostic value in probable AD (4, 5) , but the procedure is totally invasive and has thus received only little attention so far in diagnosing AD.
An accurate diagnosis of AD in the early symptomatic stage is extremely challenging despite the development of useful clinical constructs like mild cognitive impairment (MCI), which enables the identification of individuals who may be in an early clinical phase of AD. MCI was previously defined as a transitional state that can precede dementia, but the condition and the rates of conversion remain controversial. Despite many consensus conferences, experts cannot agree on critical aspects of MCI, particularly with respect to its clinical utility. Based on neuropsychological studies, a hippocampal memory profile has been proposed for MCI as prodromal AD (6) . In light of current drug development aimed at slowing AD progression, diagnosing AD at its prodromal stage is particularly important. Recently, research has begun to focus on developing new tools, such as neuroimaging and CSF biomarkers, that could increase the specificity of the prodromal AD diagnosis.
The goal of research in this area is therefore to develop highly specific and sensitive methods capable of identifying the subjects in the early stage who progress to AD. Neuroimaging markers provide an alternative and objective assessment of progression of AD. Out of various imaging techniques MRI is the most widely accepted technique to diagnose the various pathological conditions, and to monitor the treatment response, based on the changes in T 2 and T 1 contrast relaxation properties. It has been shown that the T 2 value was not significantly different between normal subjects and AD patients (7) . In one recent study, Yuan et al (8) have shown that fluorodeoxyglucose positron emission tomography (FDG-PET) performs slightly better than single photon emission tomography (SPECT) and structural imaging in prediction of conversion to AD in patients with MCI. However, the wide clinical utility of the PET technique is hampered by its poor resolution and necessity of a cyclotron at the imaging center that can produce the radioactive tracers. Other MR techniques like diffusion tensor imaging (DTI) and proton spectroscopy ( 1 HMRS) have also been used in detection of normal white matter changes in patients with AD (9,10). Ukmar et al (9) have shown a significant difference in fractional anisotropy (FA) between control and AD, while the FA was not significantly different in AD compare to MCI. Similarly, in a 1 HMRS study it has been shown that the hippocampal metabolite profile in MCI is similar to AD (10) .
An alternative contrast mechanism is T1rho (T 1 ), the spin lattice relaxation time constant in the rotating frame, which determines the decay of the transverse magnetization in the presence of a "spin-lock" radiofrequency field (11) . In biological tissue, exchange between protons in different environments is expected to contribute T 1 relaxation. The molecular process that occurs in the milliseconds range influences the T 1 relaxation time constant. T 1 MRI has been previously used to measure T 1 relaxation time in normal human brain and showed the higher range of values compared to T 2 (11) . Earlier, T 1 has been used to delineate brain tumors, characterize breast cancer tissue, and monitor the level of cartilage degeneration (12) (13) (14) .
The current study was performed with an aim to measure the baseline T 1 in hippocampus in the brain of AD (n ϭ 49), MCI (n ϭ 48), and control (n ϭ 31) cohorts and to determine whether the T 1 value shows any significant difference between these cohorts.
MATERIALS AND METHODS

Patient Selection
The Institutional Review Board approved the study protocols. In the current study we included 49 AD patients (mean age Ϯ SD ϭ 76.8 Ϯ 9.1 years), 48 MCI patients (mean age Ϯ SD ϭ 71.93 Ϯ 8.7 years), and 31 agematched controls (mean age Ϯ SD ϭ 70.2 Ϯ 9.4 years). All patients underwent a standardized clinical assessment including medical history, physical and neurological examination, psychometric evaluation, and brain MRI. The Mini-Mental State Examination (MMSE) was used as a measure of general cognitive function. The MMSE examination scores were 29.03 Ϯ 1.13 in control, 24.72 Ϯ 2.93 in MCI, and 19.34 Ϯ 6.04 in AD.
Diagnoses were made in conference by a team of neurologist, neuropsychologists, a neurophysiologist, and a psychiatrist. Diagnoses of MCI was made according to the Petersen criteria for MCI (15) and the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association criteria (NINCDS-ADRDA) for probable AD (16) . Patients were excluded if they had a history of irritable bowel syndrome, chronic diarrhea, peptic ulcer, or gastroesophageal reflux disease; a history of cardiac disease; significant electrocardiographic (ECG) abnormalities; hematologic disorders; hepatic or renal disease; active malignancy within 5 years; or clinically important depressive, neuropsychiatric, cerebrovascular, or respiratory disease. The control group consisted of patients who presented to our memory clinic with subjective complaints and underwent exactly the same diagnostic work-up as the MCI and AD patients.
MRI Protocol
All these patients underwent a standard MRI protocol on a 1.5T Siemens Sonata (Erlangen, Germany) clinical scanner using the vendor-supplied head coil. Written informed consent was obtained from each patient before they underwent MRI. For T 1 MRI, a fluid-attenuated T 1 pre-encoded Turbo Spin-Echo pulse sequence was used (11) . The imaging parameters were: TE/TR ϭ 12/2000 msec, TSL (duration of spin lock pulse) ϭ 10, 20, 30, 40 msec, with a spin lock frequency of 500 Hz, slice thickness 2 mm, field of view (FOV) ϭ 22 cm, matrix size 256 x 128, bandwidth 130 Hz/pixel, echo train length ϭ 4 for a total imaging time of 6 minutes for four images. The inversion time (TI) was fixed at 860 msec to remove the contribution from CSF to T 1 maps. An oblique coronal T 1 -weighted image of a slice perpendicular to the anterior/posterior commissure (AC/PC) plane was obtained. The slice was chosen to include the head of the hippocampus. Immediately after T 1 MRI, the entire volume of each subject's brain was imaged in the coronal plane using a T 1 -weighted 3D volumetric MPRAGE pulse sequence with 124 continuous slices. The parameters were TR/TE ϭ 3.5/3000 msec, slice thickness ϭ 1.2 mm, FOV of 24 cm and 192 phase encode steps, and flip angle 8°for a total imaging time of 10 minutes.
Data Processing
The signal expression for the T 1 -weighted MRI is given by:
where M 0 is the thermal equilibrium magnetization. The T 1 relaxation time constant is dependent on the amplitude of the SL field, which is reported as a frequency of the SL field, and typically ranges from zero to a few kilohertz. The equation was linearized and then used to generate T 1 maps by fitting all pixel intensity data as a function of TSL time using linear regression. T 1 was calculated as -1/slope of the straight-line fit (11) . Pixels whose intensities correlated poorly (R 2 Ͻ 0.95) with the fitting equation were set to zero. Pixels outside of the brain were also set to zero. The images were transformed to a G4 PowerBook computer (Apple, Cupertino, CA) and images were processed in the IDL programming language (RSI, Boulder, CO). For brain segmentation a previously developed method was used to partition the volumetric MPRAGE scans into 92 ROIs incorporating all major cortical and subcortical regions (17) . This method deforms MRI scans of different brains into anatomical coregistration with each other, and into coregistration with a standardized template. The template's labels are then transformed to individual scans by applying the elastic transformation that was found to coregister the respective images. For quantitative analysis the two regions of interest (ROIs) were defined on T 1 images, ie, left and right hippocampus. A program written in IDL was used to automatically report T 1 values from both ROIs. The coregistration of the data and the hippocampus segmentation was performed in the presence of an experienced neuroradiologist.
Statistical Analyses
For statistical analysis the T 1 value from the left and right sides were averaged for hippocampus. Descriptive statistics were performed to calculate the mean value of hippocampus T 1 for different cohorts (control, MCI, and AD). One-way analysis of variance (ANOVA) using Bonferroni post-hoc multiple comparisons was performed to compare the T 1 value among the different cohorts. Pearson correlations between T 1 values versus age and between T 1 versus MMSE score were performed separately for each cohort. A P-value of less than 0.05 was considered statistically significant. All the statistical computations were performed using the Statistical Package for Social Sciences (SPSS) v. 16 .0 (Chicago, IL). Figure 1 shows the T 1 maps of the control, MCI, and AD. Higher T 1 values are observed in the hippocampus of an AD individual compared to control and MCI individuals. The mean hippocampus T 1 values of control, MCI, and AD cohorts are reported in Table 1 and are shown in Fig. 2 . One-way ANOVA showed that the T 1 was significantly different (P ϭ 0.000) between the groups (Table 1) . Bonferroni multiple comparisons showed that the T 1 was significantly increased both in the AD (P ϭ 0.000) and MCI (P ϭ 0.037) cohorts compared to control ( Table 2) . A significant increase in T 1 was observed in AD (P ϭ 0.032) compared to MCI (Table  2 ). Hippocampus T 1 was 13% greater in the AD patients than controls, while in MCI it was 7% greater than controls. Hippocampus T 1 in AD patients was 6% greater than MCI. Even after a significant difference in the T 1 value between the three cohorts (controls, MCI, and AD), a consistent overlap in individual hippocampus T 1 value was observed (Fig. 2) . The T 1 relaxation time may be changed during the normal aging process due to relative change in the volume fractions of water and other macromolecules in the brain tissue. Therefore, we examined the age-related changes in T 1 values. None of the cohort showed the age-related changes in T 1 [control (r ϭ Ϫ0.098, P ϭ 0.606), MCI (r ϭ Ϫ0.002, P ϭ 0.988), and AD (r ϭ 0.151, P ϭ 0.306)].
RESULTS
On correlating the MMSE score with T 1 we did not find any significant correlation in any of the cohort [control (r ϭ Ϫ0.154, P ϭ 0.417), MCI (r ϭ Ϫ0.092, P ϭ 0.534), and AD (r ϭ Ϫ0.069, P ϭ 0.641)].
DISCUSSION
Discovering sensitive and specific markers of early AD would be a major breakthrough, as it would facilitate testing of novel therapeutic interventions that could slow or perhaps even arrest the degenerative process before dementia develops. In the current study we de- scribe the relevance of T 1 estimation in the early diagnosis of AD pathology. Significant increased T 1 in hippocampus of MCI and AD patients was found compared to control. Also, in AD the hippocampus T 1 was significantly increased over MCI. In the current study the hippocampus T 1 in AD patients was increased by 13% over control and by 6% over MCI. It has been shown that increased T 1 signal in AD patients is associated with the plaque burdens (18) . Even after significant differences in T 1 between three cohorts, some of the MCI and control individuals showed high T 1 values in the range of AD pathology. We believe that this overlap is probably due to the large variation in T 1 values in the MCI and control individuals.
Delacourte et al (19) proposed that the neurofibrillary degeneration in AD may be hierarchized into 10 stages, ie, starting from involvement of perirhinal cortex (Stage 1) and subsequently entorhinal cortex and hippocampus (Stage 2), and then the rest of temporal cortex (Stages 4 -6) followed by association area (Stage 7) and finally the entire cortex (Stage 10). It has been found that some subjects showed no cognitive alteration until Stage 6; most exhibited slight cognitive deficits even when most of the temporal cortex was involved (19) . An increase in the MRI relaxation time in the AD brain is certainly due to a change in the molecular environment of water in the brain parenchyma resulting from AD pathology. Since no correlation between MMSE and T 1 was observed, this suggests that the cognitive score is not sensitive to tissue pathology. However, whether there is specificity of T 1 to plaque burden or to other AD pathology remains to be determined.
Another important issue regarding the early diagnosis of AD concerns is the selection of appropriate controls. The appearance of the neuropathological hallmarks of AD, senile plaque and neurofibrillary tangles, probably occur many years before the clinical symptoms of AD. As a consequence, within the aging population, subjects with no history of cognitive problems might show a sign of AD neuropathology at autopsy. It is clear that including normal with episodic memory within the normal range does not protect against the risk of some of these subjects progressing to MCI, and ultimately to AD, during follow-up. We will follow these patients for the next 3 years with the aim to see the role of T 1 values in predicting the probability to develop AD in the future in the cognitive normal and MCI cohorts.
Hippocampus atrophy has been used to differentiate AD pathology from age-matched controls but any agerelated atrophy can confound attempts at distinguishing AD from normal control on the basis of T 1 . In the current study, however, there was no correlation between age and T 1 values, suggesting that the change in T 1 is due to an underlying pathology. It remains to be seen, perhaps by a longitudinal study, whether hippocampus T 1 in subjects with isolated memory impairment predicts a higher risk of developing AD, or, conversely, is only related to the presence of memory deficit. Longitudinal MR studies would require highly reproducible measurements of the T 1 . In an earlier work, we measured the reproducibility of the T 1 estimation in normal volunteers and the intrasubject covariance was less than 6%, but this has to be repeated on patients as well.
In the current study, measurement of T 1 was done using the two-dimensional T 1 -weighted MRI pulse sequence, which is limited to a single-slice acquisition. Recently, a three-dimensional T 1 -weighted pulse sequence has been developed by Witschey et al (21) . It was found that using this sequence the average difference was less than 5% in T 1 maps of the same brain. In general, three-dimensional sequences provide higher resolution in less time than that required for corresponding two-dimensional counterparts to acquire the same volume. Additionally, a low SAR version of T 1 mapping has been developed by Wheaton et al (22) . It was found that using this approach the SAR could be reduced by 40% along with only 2% change in the T 1 measurement in human brain.
The limitation of the current study should be emphasized, ie, any error associated with the registration between MPRAGE and T 1 image will lead inaccuracy in hippocampus segmentation, which may indirectly affect the T 1 measurement. We conclude that higher hippocampus T 1 values in AD patients might be associated with the increased plaques burden. A follow-up study would help to determine the efficacy of T 1 values as a predictor of developing AD in the control and MCI individuals investigated in this study. T 1 MRI shows promise as a diagnostic method for AD in its early stage, and can potentially be a useful biomarker for the development of putative therapeutic agents for the treatment of AD.
